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Electronic properties of DNA are believed to play a crucial role in many phenomena in living
organisms, for example the location of DNA lesions by base excision repair (BER) glycosy-
lases and the regulation of tumor-suppressor genes such as p53 by detection of oxidative dam-
age. However, the reproducible measurement and modelling of charge migration through
DNA molecules at the nanometer scale remains a challenging and controversial subject even
after more than a decade of intense efforts. Here we show, by analysing 162 disease-related
genes from a variety of medical databases with a total of almost 20, 000 observed pathogenic
mutations, a significant difference in the electronic properties of the population of observed
mutations compared to the set of all possible mutations. Our results have implications for
the role of the electronic properties of DNA in cellular processes, and hint at the possibility
of prediction, early diagnosis and detection of mutation hotspots.
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Cells tend to accumulate over time genetic changes such as nucleotide substitutions, small in-
sertions and deletions, rearrangements of the genetic sequences and copy number changes.1 These
changes in turn affect protein-coding or regulatory components and lead to health issues such as
cancer, immunodeficiency, ageing-related diseases and other disorders. A cell responds to genetic
damage by initiating a repair process or programmed cell death.2 In recent years, a vast num-
ber of detailed databases have been assembled in which rich information about the type, sever-
ity, frequency and diagnosis of many thousand of such observed mutations has been stored.3–6
This abundance of data is based on the now standard availability of massively parallel sequenc-
ing technologies.7 Harvesting these genomic databases for new cancer genes and hence potential
therapeutic targets has already demonstrated its usefulness8 and several recent international cancer
genome projects continue the required large-scale analysis of genes in tumours.9
The possible relevance of charge transport in DNA damage has recently also attracted consid-
erable interest in the bio-chemical and bio-physical literature.10–13 Direct measurement of charge
transport and/or transfer in DNA remains a highly controversial topic due to the very challeng-
ing level of required manipulation at the nano-scale.14 Ab-initio modelling of long DNA strands
is similarly demanding of computational resources and so some of the most promising computa-
tional approaches necessarily use much simplified models based on coarse-grained DNA.11 Here
we compute and datamine the results of charge transport calculations based on two such effective
models for each possible mutation in 162 of the most important disease-associated genes from four
large gene databases. The models are (i) the standard one-dimensional chain of coupled nucleic
bases with onsite ionisation potentials11, 15 as well as a novel 2-leg ladder model with diagonal
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couplings and explicit modelling of the sugar-phosphate backbone.16
Results
Point Mutations and Electronic Properties We consider native genetic sequences and mutations
of disease-associated genes as retrieved from the Online Mendelian Inheritance in Man (OMIM)3
of NCBI, the Human Gene Mutation Database (HGMD),4 International Agency of Research on
Cancer (IARC)5 as well as Retinoblastoma Genetics.6 We have selected these genes such that (i)
those from OMIM have a well-known sequence with known phenotype as well as at least 10 point
mutations, (ii) all other selected cancer-related genes have also at least 10 point mutations and (iii)
all non-cancer related genes from HGMD have at least 200 point mutations (cp. Supplementary
Table S1).
Many different types of mutation are possible in a genetic sequence including point muta-
tions, deletion of single base pairs (producing a frame shift), and large-scale deletion or duplication
of multiple base pairs. Here, we restrict our attention to point mutations as it allows us to directly
compare the sequence before and after the mutation. We study the magnitude of the change in
charge transport (CT) for pathogenic mutations when compared to all possible mutations either lo-
cally, i.e. at the given hotspot site, or globally when ranked according to magnitude of CT change.
We find that the vast majority of mutations shows good agreement with a hypothesis where small-
est change in electronic properties — as measured by a change in CT — corresponds to a mutation
that has appeared in one of the aforementioned databases of pathogenic genes.
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A gene with N base pairs (bps) has a native nucleotide sequence (s1, s2, · · · , sN ) along the
coding strand. The gene has a total of 3N possible point mutations, which we denote as the set
Mall, of which a subset Mpa are known pathogenic mutations. A point mutation is represented by
the pair (k, s), where k is the position of the point mutation in the genomic sequence and s is the
mutant nucleotide which replaces the native nucleotide. We shall write a mutation from a native
base P to a mutant base Q as “Pq”. We note that there are a total of twelve possible point mutations
in a DNA sequence (from any one of four bases to any one of three alternatives). Of these twelve,
four are transitions, in which a purine base replaces a purine or a pyrimidine replaces a pyrimidine,
and eight are transversions in which purine is replaced by pyrimidine or vice versa. Biologically,
transitions are in general much more common than transversions.17 Indeed, the set of observed
pathogenic mutations for our 162 genes contains 10999 transitions and 8883 transversions, whereas
in the set of all mutations their ratio is by definition 1 : 2. The observed pathogenic mutations are
thus already a biased selection from the set of possible mutations, favouring transitions. However,
this local onsite chemical shift is not sufficient to fully explain our data as we will show later.
We compute and datamine the results of quantum mechanical transport calculations based
on two effective Hu¨ckel models18 for each possible mutation in those 162 genes. Both models
assume π–π orbital overlap in a well-stacked double helix. The parameters are chosen to represent
hole transport. Using the transfer matrix method19, 20 we calculate the spatial extent of (hole)
wavefunctions of a given energy on a length of DNA with a given genetic sequence. Wavefunction
localisation is directly related to conductance19 and we therefore find it convenient to report our
results in terms of conductance.
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To determine the effect of a mutation, we consider sub-sequences of length L bps; there
are L such sequences that include a given site k. For all L sequences we calculate quantum-
mechanical charge transmission coefficients T (in units of e2/h¯, averaged across a range of incident
energies, as detailed in Methods) for the native and mutant sequences. We describe the effect of
the mutation on the electronic properties of the DNA strand near to the mutation site using the
mean square difference, Γ = 〈|Tnative − Tmutant|2〉, averaged across all L sequences. Larger values
of Γ therefore correspond to a greater difference in electronic structure between the native and
mutant sequences. The length L must be long enough to allow for substantial delocalisation across
multiple base pairs,21 but should remain below the typical persistence length of ∼ 150 bps22 such
that any overlap or crossing by packing, e.g. by wrapping around histone complexes in chromatin,
can be ignored. In this study we have considered lengths of 20, 40, 60 bps. This requires, for each
of the N sites in a gene, L calculations for each sequence of length L and for each of 4 possible
bases at that site; which, for the more than 11× 106 bases in our dataset of 162 genes, is more than
5× 109 quantum mechanical transport calculations.
Local and global ranking We first compare Γ of each observed pathogenic mutation with the
other two non-pathogenic ones at the same position and determine a local ranking (LR) of CT
change. There are three possibilities of LR, namely low, medium and high. Note that those hotspots
with more than one pathogenic mutations are excluded in the LR analysis. We have also sorted
the LR ranking for each gene according to prevalence in Fig. 1(a+b). We find that for L = 20, 40
and 60 the low CT change corresponds to 155 (95%), 148 (91%) and 140 (86%) of all 162 genes
with pathogenic mutations. Examples of LR for the pathogenic mutations of p16 and CYP21A2
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are shown in Supplementary Fig. S3. We graphically summarise the results for all 162 disease-
associated genes in Fig. S5. For each gene, we have shown a positive deviation from the 33%
line by orange —supporting the scenario of small CT change for pathogenic mutations — and by
blue when the results seem to show no or negative indication with CT change. It is clear that the
correlation between low CT change and mutation hotspots is well pronounced.
We can also consider a global ranking (GR) by sorting CT change Γ for all possible 3N
mutations of a gene with N bps in order to get a ranking of every observed pathogenic mutation.
By dividing each ranking by 3N we compute the normalised GR γ of the mutation, with values
between 0 and 1. Smaller values of γ mean smaller CT change. By analogy to the local ranking,
we divide the γ of the pathogenic mutations into three groups as before, i.e. low (γ < 33.3%),
medium (33.3% ≤ γ < 66.7%), and high (γ ≥ 66.7%) CT change. The results of the GR for the
162 genes are shown in the bottom row (c) and (d) of Fig. 1. As for the LR results, we observe
many γ values with low CT change (cp. Supplementary Figs. S3and S4). Hence the LR and GR
results consistently show that observed pathogenic mutations are generally biased towards smaller
change in CT than the set of all possible mutations (cp. Supplementary Figs. S5and S6).
Distributions of change in charge transport In Figure 2 we show as an example results for the
distribution of Γ for the p16 DNA strand for both 1D and 2-leg models. In panels (a+b), it is clear
that the 111 observed pathogenic mutations of p16 have on average smaller changes in the CT
properties as compared to all possible 80220 mutations, for both the 1D and 2-leg models. We find
that results for the vast majority of the other 161 genes are quite similar. The distributions of Γ
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values in Fig. 2(a+b) are approximately log-normal. We therefore calculate, for each of the 162
genes in our dataset, an average log Γ value for the distributions of all and pathogenic mutations.
Histograms of the distributions of these 〈log Γ〉 values are shown in Fig. 2(c+d). It is once again
clear that the distributions for observed pathogenic mutations are shifted towards lower Γ values
in both the 1D and the 2-leg models.
We next define a global CT shift for a gene g as Λg = 〈log Γg,all〉 − 〈log Γg,pa〉. Positive
values of Λg indicate that the observed pathogenic mutations of gene g have a lower average Γ.
For each of our 162 genes we obtain the distribution of Λg for the 1D and 2-leg models as shown in
Figs. 2(e+f). We can define, for the whole set of 162 genes, an average global shift Λ¯ = ∑g Λg/162,
weighting all genes equally; we can also weight the results by the number of observed pathogenic
mutations for each gene |Mpa|g for a weighted average global shift Λ˜ = 1∑
g
|Mpa|g
∑
g |Mpa|gΛg.
These values are also indicated in Figs. 2(e+f) and in both models there is a tendency towards
lower average Λ¯g for observed pathogenic mutations.
Transitions and transversions In our models we would expect transitions to cause, in general, a
smaller change in CT than transversions, as the change in onsite energy and in transfer coefficients
is smaller for a transition than a transversion. However, as we will demonstrate here, the increased
proportion of transitions among the observed pathogenic mutations is not sufficient to account for
the distributions seen in Fig. 2.
In Fig. 3(a+b) we show the distribution of Γ values for our entire dataset of all ≃ 34 × 106
possible mutations and 19882 known pathogenic mutations, dividing the datasets into transitions
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and transversions. For both models, the transitions are shifted to slightly lower Γ values than the
transversions. However, in the 2-leg model, the distribution for observed pathogenic transitions
appears co-located with the distribution for all transitions, and likewise for transversions. In the
1D model, by contrast, the observed pathogenic transitions are visibly shifted to lower Γ values
than the set of all transitions, and the same is true for transversions.
In Fig. 3(c+d) we represent the distributions of Γ values for each of the twelve types of point
mutation by points for the mean values of log Γ and bars indicating the standard deviation of the
distribution of log Γ. In the 2-leg model, the distributions for observed pathogenic mutations are
essentially coincident with the distributions for all mutations for each type Pq. The positive Λ¯
and Λ˜ shift results in the 2-leg model are thus accounted for by the set of observed pathogenic
mutations being biased towards transitions. The 1D model displays a quite different behaviour;
in each case the mean of the distribution for the observed pathogenic mutations of any type Pq,
lies from 7.5 to 20 standard errors below the mean for all possible mutations of type Pq. Hence
the probability that the observed pathogenic mutations are a random subset of all mutations, with
respect to their electronic properties in the 1D model, is comparable to the probability of drawing
twelve values more than 7.5 standard deviations below the mean from a normal distribution, which
is less than 10−168. The observed difference between CT change between observed pathogenic and
all possible mutations is thus statistically highly significant irrespective of whether transitions or
transversions are involved. In the 2D model, by contrast, the means of the log Γ distributions for
observed pathogenic mutations can lie either above or below those for all mutations for different
types Pq, and the difference in the means — between 0.03 and 5.5 standard errors — is much
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smaller.
Let us also consider, for each gene g, simulation length L and each mutation type Pq whether
the subset shift λ = 〈log Γall〉 − 〈log Γpa〉g,L,Pq is positive or negative. This gives us, for each
model, 162 × 3 × 12 = 5832 data points, less 1029 cases where no calculation is possible as no
pathogenic mutations of type Pq are known for gene g. These λ data are presented in Fig. 4. In
the 2-leg model there are approximately equal numbers of negative and positive λ values. This
is consistent with a null hypothesis where the observed pathogenic mutations of a type Pq have
the same distribution of Γ vales as for all mutations of that type. In the 1D model, by contrast,
such a null hypothesis is decisively rejected: there is a preponderance of positive λ values by
almost 2 : 1 (3326 positive to 1513 negative) and the binomial probability of obtaining such a
result at random would be approximately 10−153. The two analyses agree that observed pathogenic
mutations display a significant bias towards smaller changes in electronic properties in the 1D
model.
Discussion
Our CT models act as probes of the statistics of the DNA sequence. It is possible that we are merely
observing a correlation; i.e. that mutations are more likely to occur in areas of the genome with
certain statistical properties, for reasons not causally related to charge transport, and these prop-
erties correlate with biased CT properties in our 1D model. Such a correlation between quantum
transport and mutation hotspots would in itself be a valuable and novel observation in bioinfor-
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matics. There are known chemical biases in the occurence of mutations, such as the enhanced
transition rate in C-G doublets,23 the bias towards GC base pairs rather than AT pairs in biased
gene conversion24, 25 and the tendency of holes to localise on GG and GGG sequences and there
cause oxidative damage.26 However, since our observed bias is consistent across all twelve types
of point mutation, these known biases cannot fully account for our data.
There are also plausible causal connections between our data and cellular genetic processes
where the electronic properties of DNA may be significant. One such process is gene regula-
tion, where charge transport along the DNA strand can couple to redox processes in DNA-bound
proteins, inducing protein conformational change and unbinding.27 Similarly, it has been proposed
that DNA repair glycosylases containing redox-active [4Fe-4S] clusters28 may localise to the site of
DNA lesions through a DNA-mediated charge transport mechanism.29 The recognition of specific
areas in the DNA sequence by DNA-binding proteins generally may involve electrostatic recogni-
tion of the target DNA sequence.30 Furthermore, homologous recombination31 — a process which
is vital to the repair of double-strand breaks, a most serious DNA lesion,32, 33 and also to genetic
recombination — relies on the mutual recognition of homologous chromosomes before strand in-
vasion can occur. Homologous double-stranded DNA sequences are capable of mutual recognition
even in a protein-free environment,34 presumably via electronic or electrostatic interactions.35
All the above processes, especially those involving protein–DNA or DNA–DNA recognition,
would be less disrupted by a smaller change in the electronic environment along the coding strand.
From this point of view, the observed mutations are biased to cause less disruption to gene regula-
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tion and DNA damage repair in the cell. This may seem counterintuitive at first. However, in order
for a mutation to appear in our dataset of pathogenic mutations, the cell and the organism must
develop viably for long enough for a mutant phenotype to be observed. Mutations which cause
large disruptions to DNA regulation and repair are more likely to be lethal to the cell at an early
stage and will thus be absent from disease databases. Similarly, mutations which are more visible
to DNA repair mechanisms are less likely to persist and to appear in databases.
Genetic repair and regulation mechanisms cannot know whether the consequences of a mu-
tation are beneficial, neutral or harmful. We would therefore predict that neutral mutations should
display the same bias, towards smaller change in electronic structure, as we observe in the pathogenic
mutations. As a first test of this prediction, we have considered the case of the TP53 gene, with
20303 base pairs and for which there are known 2003 pathogenic mutations, 366 silent mutations
and 113 intronic mutations.5 We have simulated these silent and intronic mutations using the 1D
model. Histograms of the distribution of Γ values for these mutations are given in supplementary
material, see Fig. S7. In Table 1 we analyze the statistical properties for the resulting Γ distribu-
tions; our results demonstrate that, for both transitions and transversions, the silent and intronic
mutations are similar to the pathogenic mutations and significantly disimilar to the population of
all possible mutations, as predicted.
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Methods
Models of charge transport in DNA. The simplest model of coherent hole transport in DNA
is given by an effective one-dimensional Hu¨ckel-Hamiltonian for CT through nucleotide HOMO
states,11 where each lattice point represents a nucleotide base (A,T,C,G) of the chain for n =
1, . . . , N . In this tight-binding formalism, the on-site potentials ǫn are given by the ionisation
potentials ǫG = 7.75eV, ǫC = 8.87eV, ǫA = 8.24eV and ǫT = 9.14eV, at the nth site, cp. Fig. 5; the
hopping integrals tn,n+1 are assumed to be nucleotide-independent with tn,n+1 = 0.4eV.11 A model
which is less coarse-grained is provided by the diagonal, 2-leg ladder model shown in Fig. 5. Both
strands of DNA and the backbone are modelled explicitly and the different diagonal overlaps of
the larger purines (A,G) and the smaller pyrimidines (C,T) are taken into account by suitable inter-
strand couplings.16, 36 The intra-strand couplings are 0.35eV between identical bases and 0.17eV
between different bases; the diagonal inter-strand couplings are 0.1eV for purine-purine, 0.01eV
for purine-pyrimidine and 0.001eV for pyrimidine-pyrimidine. Perpendicular couplings to the
backbone sites are 0.7eV, and perpendicular hopping across the hydrogen bond in a base pair is
reduced to 0.005eV.
The 2-leg model16 allows inter-strand coupling between the purine bases in successive base
pairs, in accordance with electronic structure calculations 36, and should therefore be a better model
for bulk charge transport along the DNA double helix; the 1D model, by contrast, makes use of
the site energies of only the bases on the coding strand, 15 and so is most representative of the
electronic environment along that strand. We also find that the 2-leg model recovers some of the
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coding strand dependence of the 1D model upon decreasing the diagonal hoppings. For 28 genes,
we find that reducing only the diagonal hopping elements by two leads to a much greater agreement
with the 1D results similar to Fig. 3(c).
Calculation of quantum transmission coefficients. The quantum transmission coefficient T (E)
for a DNA sequence with length N bps for different injection energy E can be calculated for
both models by using the transfer matrix method.20, 37 Let us define Tj,L(E) as the transmission
coefficient for a part of a given DNA sequence which starts at base pair position j and is L base
pairs long. The position-dependent averaged transmission coefficient at the k−th base pair for
transmission length L bps is defined as
T
(k)
L =
1
L
k∑
j=k−L+1
∫ E1
E0
Tj,L(E)
E1 − E0
dE . (1)
Here j ranges from k − L + 1 to k such that each subsequence of length L contains the kth base
pair. E0 and E1 are the lower and upper bounds of the incident energy of the carriers, e.g. for
the 1D model used here, the values are 5.75 and 9.75eV, respectively; for the 2-leg model the
bounds are 7 and 11eV. We have used an energy resolution of ∆E = 0.005eV. Then we examine
the difference between transmission coefficients of the normal and mutated genomic sequence of
a point mutation15 and hence denote by T (k,s)j,L the transmission coefficient of the same segment of
DNA as T (k)j,L but with the point mutation (k, s). Γ
(k,s)
L is the averaged effect of the point mutation
(k, s) on CT properties for all subsequences of length L containing the mutation,
Γ
(k,s)
L =
1
L
k∑
j=k−L+1
∫ E1
E0
|Tj,L(E)− T
(k,s)
j,L (E)|
2
E1 −E0
dE . (2)
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log10 Γ SEM σ pall ppa
All transitions −1.753 0.003 0.427 - -
Pathological transitions −1.840 0.015 0.431 1.01×−8 -
Silent transitions −1.868 0.029 0.440 6.62× 10−5 0.391
Intron transitions −1.805 0.048 0.391 0.320 0.526
All transversions −1.605 0.002 0.422 - -
Pathological transversions −1.710 0.012 0.4190 < 10−10 -
Silent transversions −1.691 0.036 0.432 0.016 0.610
Intron transversions −1.739 0.054 0.337 0.032 0.636
Table 1: Mean logarithm of CT change Γ for gene TP53 using the 1D model withL = 20. Data are divided
into transition and transversions. We give standard errors of the mean (SEM) and standard deviations (σ)
for each distribution. From these we estimate the probability of each distribution being a random sample
from the set of all mutations, pall, or being a sample from a population similar to the pathogenic mutations,
ppa (cp. Fig. S7). There are 224 silent transitions and 142 silent transversions; 67 intronic transitions and
46 intronic transversions. The pathogenic mutations and all possible mutations outnumber the silent and
intronic populations by factors of 10–1000 and so it is the SEM for the smaller populations that is significant.
It is clear that the mean CT change log10 Γ for the silent and intronic populations is far more similar to the
pathogenic populations than to the entire population of all possible mutations. This is true for both transitions
and transversions, although the p-value for the intronic transitions is not statistically significant (i.e. ≥ 0.05)
which we attribute to the small number of available intronic data.
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Figure 1: Sorted prevalence of the low, medium and high CT change among local (a+b) and global
(c+d) rankings for pathogenic mutations in 162 genes using the 1D (a+c) and the 2-leg (b+d)
models. Results are consistent for all three lengths L = 20, 40, 60. The 1/3 value expected by
chance is shown as a dashed horizontal line. Low rankings are dramatically more prevalent locally
and globally than chance would suggest.
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Figure 2: (a+b) Distribution of the change in charge transport Γ for pathogenic (orange bars) and
all possible (cyan bars) mutations for the p16 (CDKN2A) gene with 26740 base pairs and 111
known pathogenic mutations. (c+d): Distribution of the average (logarithmic) change in charge
transport 〈log Γ〉 for all pathogenic (orange bars) and all possible (cyan bars) mutations for all
162 genes. (e+f): Distribution of the global shift Λ values for all genes, showing a consistent
tendency to positive values. The average Λ¯ (dashed) and weighted average Λ˜ (dash-dotted) values
are indicated by vertical lines similarly to the 0 line (dotted). The grey bars denote the error of
mean for
〈
Λ¯
〉
. The results for the 1D and 2-leg models are displayed in panels (a,c,e) and (b,d,f),
respectively. All results shown are for L = 40, data for L = 20 and 60 are similar.
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Figure 3: Distributions of Γ for the 1D (a) and 2-leg (b) models for all genes, with mutations
divided into transitions and transversions. The distributions are normalised by the size of the
mutation dataset. Lines are guides to the eye only. The means (symbols) and standard deviations
(error bars) of the distributions of log Γ are shown in panels (c) and (d) for the 1D and 2-leg models.
Estimated errors of the means are smaller than the symbols. Distributions are shown for transition
(Ti) and transversion (Tv) mutations, and for the twelve types of point mutation individually. Open
symbols (blue, cyan) are for the set of all mutations, filled symbols (orange, red) for the set of
pathogenic mutations.
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Figure 5: Schematic models for charge transport in DNA. The nucleobases are given as circles
(red, denoting pairs) and ellipses (blue, brown for single nucleotides). Electronic pathways are
shown as solid lines of varying thickness to indicate variation in strength. Model (a) indicates the
1D model where the sugar-phosphate backbone is ignored. In model (b), brown circles denote
the smaller pyrimidines, blue ellipses are the large purines and green circles denote the sugar-
phosphate backbone sites. Note that diagonal hopping between purines is favoured, and between
pyrimidines disfavoured, by the larger size of the purines.
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Supplementary Material
Comparing the Averaged Electronic Properties for the Pathogenic and Non-pathogenic Mu-
tations for Each Gene
We denote the genomic sequence of a gene with length N base pairs (bps) as (s1, s2, · · · , sN ).
Each point mutation of a given gene is characterized by the set (k, s), where k and s are the
position of the point mutation in the genomic sequence and the mutant nucleotide which replaces
the nucleotide sk of normal DNA, respectively. There are totally 3N possible point mutations of a
gene with N bps. The sets of these 3N mutations and the pathogenic mutations for the gene are
denoted as Mall and Mpa, respectively. Mpa is a subset of Mall. For every possible point mutation,
we compute the mean quantum mechanical transmission coefficient T (k)L of a subsequence with
length L of the wild-type gene. Here the mean is determined by averaging over all individual
transmission coefficients Tj,L with j = k − L + 1, k − L + 2, . . . , k. In this way, the influence
of the full neighborhood of hotspot k is taken into account and not just the mutation itself. The
results of T (k)L for k ∈ Mpa already show some signatures of atypical CT reponse for the 1D
model.38 However, the signal is much less pronounced in the 2-leg model. Hence we study the
difference in CT between a healthy DNA base and the 3 possible mutations. For example the
hotspot 14585 of p53 contains the correct C/G base pair in the wild but of the three possible
mutations C/G → G/C, C/G → A/T and C/G → T/A only the last one is know to lead to
cancer.5 Averaging again over all incident energies and subsequences of length L containing the
1
hotspot (k, s), we can characterize the average change in CT as
Γ
(k,s)
L,q =
1
L
k∑
j=k−L+1
∫ E1
E0
|Tj,L(E)− T
(k,s)
j,L (E)|
q
E1 −E0
dE . (3)
with q = 1 or 2. We find that results for q = 1 and 2 are similar. Hence in the manuscript we
restrict our discussion to q = 2. We calculate such Γ estimates for all possible 3N mutations
of each gene and compare the probability distribution of CT change Γ(k,s)L,q for (k, s) ∈ Mall and
(k, s) ∈ Mpa for each gene. The result for the p16 gene was shown in Fig. 2(a) as an example.
As a control group, we also shuffled the p16 sequence randomly under the conditions that (1) the
contents of the 4 bases are not changed, and (2) the positions of the mutations can be moved but
the numbers of the 12 types of mutations are not changed. The distributions of the averaged Γ for
1D and 2-leg models with L = 40 of the 20 shuffled sequences are shown in Fig. S1. It is clear
that the distributions of Γ for the Mall and Mpa are almost identical.
CT Change for the 12 Type of Mutations
The comparison of Γ between the pathogenic and all possible mutations for the 12 types of point
mutations is shown in Fig. S2. It is clear for the 1D model (a–l) Γ tends to be smaller for the
pathogenic mutations. However, the difference is not visible for the 2L model (m–x).
Local ranking of point mutations at hotspot sites
In order to study the local effects of pathogenic mutations on CT, we compare Γ(k,s)L,2 of each
pathogenic mutation (k, s) with the other two non-pathogenic ones at the same position k and de-
2
termine the local ranking (LR) of CT change for (k, s). There are three possibilities of LR, namely
low, medium and high. Note that those hotspots k with more than one pathogenic mutations are
excluded in the LR analysis. As an example, percentages of the three LR for the pathogenic muta-
tions of p16 are shown in the left panels of Fig. S3. of pathogenic mutations with low CT change
are evidently larger than the medium and high ones for all L. Let us again ask how significant this
tendency is across all 162 genes. Figure S4 shows similar ranking analysis results as in Fig. S3 but
now for all Mpa. We see that the tendency towards low CT change in the pathogenic mutations is
quite strong overall. In Fig. 1 we have sorted the LR ranking for each gene according to prevalence.
We find that for L = 20, 40 and 60 the low CT change corresponds to 155 (95%), 148 (91%) and
140 (86%) of all 162 genes with pathogenic mutations. Note that similarly consistent is the result
for large CT with only about 30 of all genes having high CT change.
Global CT rankings at hotspot sites
Another way to compare the CT change is a global ranking (GR). We have sorted the CT change
Γ
(k,s)
L,2 for all possible 3N mutations of a gene with N bps in order to get a ranking of every
pathogenic mutation (k, s). By dividing each ranking by 3N we compute the normalised GR γ(k,s)L,2
of the mutation with values between 0 and 1. As before for Γ(k,s)L,q , smaller values of γ
(k,s)
L,q mean
smaller CT change. To characterise the CT change in a quantitative way, we divide the γ(k,s)L,2
of the pathogenic mutations into again three groups as before, i.e. low (γ < 33.3%), medium
(33.3% ≤ γ < 66.7%), and high (γ ≥ 66.7%) CT change. The distributions of the GR for
the complete set of pathogenic mutations of p16 is shown in Fig. S3 as an example. As for the
3
LR results, the pathogenic genes lead to many γ(k,s)L,2 values with low CT change. This is most
pronounced in the 1D model as shown in Fig. S3(c). The results of the GR for the 162 genes
are shown in the bottom row (c) and (d) of Figs. S4 and 1. We see that the GR results are fully
consistent with the LR rankings.
Consistency of CT rankings for all DNA sequences
The prevalence ordering as shown in Fig. 1 does not imply that the order of the genes themselves is
the same in all parts (a), (b), (c) and (d) of the figure. Therefore we have calculated the correlations
in the ordering and found that in both models and across models and for all L = 20, 40 and 60,
we find positive correlation coefficients. Hence genes which have a low change in CT for, e.g.,
the local ranking at L = 20, also retain this low rank for the other L values as well as the global
ranking. Similarly, this positive correlations implies that in those few case where the mutations in
a gene lead to high CT change, they do so across all local as well as global rankings. This confirms
that our results are internally consistent.
We graphically summarise the results for all 162 disease-related genes in Fig. S5. For each
gene, we have shown a positive deviation from the 0.33 line by orange —supporting the scenario
of small CT change for pathogenic mutations — and by blue when the results seem to show no or
negative indication with CT change. The criteria corresponds to local and global ranking results
for L = 20, 40 and 60 for the 1D and the 2-leg models. Similarly, in Fig. S6, we average of all
12 criteria and show the resulting, overall agreement with the CT hypothesis: 161 of 162 genes are
4
above the 33% line and hence show that for both 1D and 2-leg model and averaged over lengths 20,
40 and 60, a small CT change correlates with the existence and position of pathogenic mutations.
Only for STK11 do we see that there is no overall agreement.
Difference and similarities in the two models
The 2-leg model16 allows inter-strand coupling between the purine bases in successive base pairs,
in accordance with electronic structure calculations,36 and should therefore be a better model for
bulk charge transport along the DNA double helix; the 1D model, by contrast, makes use of the site
energies of only the bases on the coding strand,15 and so is most representative of the electronic
environment along that strand. We also find that the 2-leg model recovers some of the coding
strand dependence of the 1D model upon decreasing the diagonal hoppings. For 28 genes, we find
that reducing only the diagonal hopping elements by 1/2 leads to a much greater agreement with
the 1D results similar to Fig. 3(c).
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Figure S1: (Supplementary) Distribution of the change in charge transport in (a) 1D and (b) 2L
models Γ for pathogenic (orange bars) and all possible (cyan bars) mutations averaged for the 20
shuffled p16 (CDKN2A) DNA strands with 26740 base pairs. All results shown are for L = 40,
data for L = 20 and 60 are similar.
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Figure S2: (Supplementary) Panels a-l: 1D model, results divided into the twelve subtypes of mu-
tation. The shift for pathogenic mutations is clearly present in every case. Panels m-x: 2L model,
results divided into the twelve subtypes of mutation. There is no consistent shift for pathogenic
mutations.
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Figure S3: (Supplementary) Distribution of the local (a+b) and global (c+d) ranking results of
pathogenic mutations of p16 (CDKN2A) (blue solid lines) and CYP21A2 (green) as a function of
window lengths L. The dashed lines indicate averaged results for 20 randomly shuffled p16 se-
quences. The left/right columns distinguish results for the 1D/2-leg models. The dashed horizontal
line shows the 33% mark expected for a completely random sequence. All lines are guides to the
eyes only. Error bars are within symbol size.
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Figure S4: (Supplementary) Distribution of the local (a+b) and global (c+d) ranking results of all
19882 pathogenic mutations of the 162 genes as a function of window lengths L. The left/right
columns distinguish results for the 1D/2-leg models. The dashed horizontal lines show the 33%
mark of a completely random sequence. All lines are guides to the eyes only.
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Figure S7: Histograms of Γ distributions for (a) transitions and (b) transversions in TP53, simu-
lated using the 1D model and L = 20. Histograms are shown for all possible mutations and for
pathogenic, silent and intronic subsets. The maximum heights of the populations are scaled to be
2, 1.5, 1 and 0.5 to ease comparison. The scales factors are indicated by the dotted horizontal lines.
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Table S1: (Supplementary) List of the 162 genes with their lengths
(bps), number of all point mutations (Npa), and their numbers of
the 12 types of point mutations. For example, NAt means the num-
ber of A→ T substitution.
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
ABCA1 147154 87 0 4 9 2 7 2 4 24 3 18 7 7
ABCA4 128313 382 11 9 21 13 51 21 27 73 19 99 23 15
ABCD1 19894 223 8 7 14 6 31 3 15 46 17 47 13 16
ACTA1 2852 164 10 7 22 5 13 6 13 12 11 29 17 19
ACTC1 7631 14 0 1 3 0 0 0 0 4 1 2 1 2
AGA 11668 19 0 0 0 1 3 1 0 2 0 8 2 2
AGT 11673 10 0 0 1 0 1 1 0 5 0 1 0 1
ALB 17127 63 3 2 13 2 1 0 1 6 1 24 4 6
ALDOB 14448 28 0 0 0 1 9 1 3 5 3 3 1 2
AMPD3 56903 11 0 1 0 1 1 0 0 6 1 0 0 1
ANK1 144397 18 0 0 1 0 2 0 1 7 1 4 2 0
APC 108353 222 10 0 4 18 1 8 21 83 28 18 28 3
APOB 42645 51 0 0 2 4 1 1 3 26 2 8 3 1
APOE 3612 33 0 1 1 0 2 0 2 9 2 9 2 5
APRT 2466 13 2 0 1 0 3 0 0 1 0 4 1 1
AR 180246 299 11 6 24 11 31 12 22 53 25 56 31 17
13
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
ASAH1 28574 12 1 0 3 1 0 0 1 0 3 1 0 2
ATM 146268 169 8 3 20 9 11 15 5 55 10 19 8 6
ATP7B 78826 315 10 14 25 14 27 10 17 62 16 68 30 22
BCAM 12341 14 1 0 1 1 0 0 1 4 1 5 0 0
BCHE 64562 58 6 2 6 3 6 3 2 12 0 8 5 5
BRCA1 81155 301 12 6 30 14 29 23 12 63 15 38 50 9
BRCA2 84193 162 12 9 20 8 11 8 12 33 13 15 19 2
BRIP1 180771 13 1 0 0 0 1 1 0 3 2 2 1 2
BTK 36741 329 15 14 29 19 47 23 26 44 14 48 32 18
CAPN3 64215 213 2 9 18 5 23 6 10 45 19 48 14 14
CASR 102813 144 2 5 12 4 21 7 8 20 10 38 12 5
CBS 23121 107 2 1 6 4 10 0 4 24 7 39 2 8
CD55 38983 14 0 0 1 2 0 1 0 4 0 3 1 2
CDH1 98250 30 0 1 2 0 2 2 0 9 1 8 4 1
CDKN2A 26740 71 1 3 4 2 6 6 5 12 3 11 8 10
CFC1 6748 10 0 0 0 0 1 0 0 4 1 4 0 0
CF 188699 828 35 31 103 50 85 54 47 117 41 136 84 45
CFH 95494 83 3 3 8 6 10 5 2 10 6 14 13 3
CHEK2 54092 20 1 1 2 0 1 0 2 4 0 7 1 1
COL1A1 17544 292 0 2 2 0 1 2 1 21 4 134 79 46
COL2A1 31538 124 0 1 2 1 1 1 5 26 0 53 19 15
14
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
COL4A5 257622 244 2 0 4 2 2 5 4 20 1 117 55 32
COL7A1 31088 265 0 3 6 2 1 0 1 56 7 122 34 33
CPOX 14152 36 0 2 1 0 3 1 0 14 2 9 3 1
CRB1 210178 91 3 1 2 8 16 7 3 11 2 22 11 5
CRX 21483 18 0 1 1 0 0 1 2 4 0 8 0 1
CRYAA 3773 10 0 0 0 0 0 0 1 5 0 3 1 0
CRYGD 2882 12 0 1 0 0 0 0 4 3 1 2 1 0
CYB5R3 30587 35 0 0 3 0 6 2 2 12 0 10 0 0
CYP19A1 129126 13 0 0 0 0 2 1 0 5 0 5 0 0
CYP21A2 3338 102 4 4 5 7 8 4 6 23 2 25 4 10
CYP2A6 6897 12 1 0 1 1 2 0 0 2 0 2 2 1
DPYD 843317 34 2 3 7 2 0 1 2 7 0 5 4 1
DSP 45077 20 0 0 2 1 1 1 0 6 1 6 1 1
ERCC6 80364 18 1 0 2 1 1 1 0 10 1 1 0 0
F10 26731 81 1 4 5 1 6 2 4 11 3 33 5 6
F11 23718 131 2 5 6 3 17 3 9 28 2 29 13 14
F13A1 176614 55 1 0 2 0 6 4 4 12 3 14 8 1
F2 20301 42 0 3 3 0 1 1 0 11 1 17 3 2
F7 14891 164 4 1 13 1 17 4 9 30 6 55 13 11
F8 186936 1168 79 47 124 56 117 78 55 153 72 198 112 77
F9 32723 707 31 26 55 58 69 52 42 54 28 135 95 62
15
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
FAH 33342 26 2 1 2 0 1 3 2 6 0 5 4 0
FANCD2 75502 14 0 0 0 0 3 3 0 4 0 4 0 0
FANCG 6179 16 0 0 0 0 2 1 0 7 0 2 2 2
FBN1 237414 640 18 12 52 32 88 37 21 63 32 173 68 44
FECH 38454 49 2 1 2 3 7 3 1 11 1 11 4 3
FGA 7618 45 3 1 3 3 1 2 3 12 2 7 7 1
FLCN 24971 11 0 0 1 0 0 0 0 4 2 3 1 0
FUT1 7380 22 0 0 1 2 2 1 2 5 1 4 1 3
FUT3 8587 11 0 0 0 1 0 2 2 0 0 5 0 1
G6PC 12572 66 2 2 3 2 8 3 3 13 2 15 5 8
G6PD 16182 163 3 3 21 4 15 4 8 27 15 39 13 11
GAMT 4465 11 0 2 0 0 1 0 0 1 1 3 1 2
GBA 10246 259 8 11 25 8 32 19 14 42 10 53 19 18
GCK 45153 255 5 13 15 7 32 8 19 40 11 64 23 18
GH1 1636 35 2 2 7 0 3 1 1 5 2 7 3 2
GJB1 10004 240 4 5 25 18 31 12 10 39 24 39 17 16
GJB2 5513 208 8 9 19 5 28 8 12 23 15 49 19 13
GNAS 71456 51 2 2 2 1 6 2 1 17 4 9 3 2
GPR143 40464 43 2 0 3 2 4 3 4 6 1 10 4 4
HBA1 842 73 2 5 9 2 5 2 7 6 9 8 7 11
HBB 1606 263 15 20 20 21 23 16 22 26 18 38 20 24
16
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
HFE 9612 27 1 2 0 0 4 1 0 3 2 7 3 4
HMGCL 23583 27 2 0 2 0 3 1 1 4 1 8 3 2
HSD11B2 6421 24 1 0 1 0 3 2 1 12 1 3 0 0
HSD3B2 7879 32 0 1 1 1 2 3 3 8 3 6 2 2
IDS 26493 203 15 8 15 2 16 13 17 31 19 32 20 15
INS 1431 30 0 0 2 0 3 2 1 3 6 6 4 3
IRS1 64538 14 0 1 3 0 1 0 1 2 1 3 0 2
ITGB3 58870 53 2 2 3 1 10 4 1 12 1 11 5 1
JAG1 36257 131 2 0 3 6 11 6 11 30 12 28 16 6
KAL1 203313 25 0 0 1 2 1 1 1 9 2 6 1 1
KCNE1 65586 17 0 0 1 0 2 0 1 5 0 6 1 1
KCNH2 32966 266 8 11 27 5 19 12 15 61 9 43 35 21
KCNQ1 404120 226 3 2 19 8 24 5 12 44 13 61 11 24
KEL 21303 33 2 0 3 1 3 0 0 9 1 13 0 1
LDHB 22501 11 1 1 1 0 1 2 1 1 0 2 0 1
LDLR 44450 741 23 31 48 31 84 35 51 88 48 168 92 42
LHCGR 68951 37 2 3 3 3 7 3 2 7 1 3 2 1
LIPC 136898 11 0 1 2 0 0 1 0 2 0 4 0 1
MAPT 133924 36 3 2 2 0 3 2 2 6 1 9 5 1
MC1R 2360 24 0 1 1 0 4 0 3 8 0 5 1 1
MEN1 7779 239 10 7 8 9 26 11 19 44 14 38 33 20
17
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
MLH1 57359 275 16 15 26 18 19 17 18 42 20 36 28 20
MLH3 37769 17 0 1 5 0 1 0 0 2 1 4 2 1
MSH2 80098 238 16 11 25 8 9 14 11 62 14 30 25 13
MSH6 23872 54 3 1 5 2 3 0 3 17 6 7 4 3
MYH7 22924 268 8 10 20 4 19 8 16 47 17 80 16 23
NF1 282701 338 22 4 24 20 35 26 14 82 24 44 29 14
NF2 95023 72 5 2 5 2 6 1 2 25 4 7 11 2
NPC1L1 28781 26 0 0 3 2 0 0 0 11 1 8 1 0
NR3C1 157582 14 1 0 1 1 4 1 0 1 0 4 0 1
OAT 21580 42 0 0 2 2 4 0 3 9 2 11 5 4
OTC 68968 276 16 11 28 9 31 18 17 36 15 44 27 24
PDE6B 45199 20 1 0 0 3 3 1 2 5 1 4 0 0
PEX1 41509 24 0 0 0 0 4 1 2 7 3 6 0 1
PEX26 11503 10 0 0 0 0 3 0 0 3 2 2 0 0
PEX6 15143 18 0 1 0 0 3 1 1 7 0 5 0 0
PEX7 91337 24 1 2 2 1 1 3 2 6 1 4 1 0
PHKA2 91305 23 0 1 2 0 0 1 1 11 0 5 2 0
PKD1 47189 149 2 3 6 5 12 4 8 59 10 27 8 5
PKD2 70110 35 1 0 1 1 1 1 2 17 0 7 3 1
PKHD1 472279 213 8 10 22 7 29 9 7 50 7 38 17 9
PMS2 35868 21 3 1 1 1 0 0 0 6 0 5 4 0
18
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
POU1F1 16954 22 1 0 2 1 3 1 1 6 0 4 2 1
PROC 10802 203 6 6 10 3 21 6 15 40 8 55 13 20
PRSS1 3592 26 1 2 2 2 2 0 2 5 1 5 2 2
PSEN1 83931 154 6 8 13 8 22 11 7 21 12 19 16 11
PSEN2 25532 18 2 2 3 0 0 0 0 5 1 5 0 0
PTCH1 73984 59 3 2 1 2 4 2 7 15 2 11 8 2
PTEN 105338 98 2 2 10 9 13 11 5 15 8 15 6 2
PTS 7595 27 1 0 8 1 0 2 0 6 2 4 2 1
QDPR 57702 20 0 1 2 0 3 3 0 3 0 6 1 1
RB 180388 226 9 8 18 12 16 11 10 38 8 51 28 17
RP2 45418 17 0 0 1 0 1 2 0 5 2 4 2 0
RPE65 21136 42 1 1 2 1 5 3 3 9 1 7 7 2
RPGRIP1 63325 24 0 2 5 1 0 0 0 7 0 5 3 1
RS1 32422 93 3 0 7 5 11 4 5 15 5 19 7 12
RYR1 153865 244 5 4 21 9 20 6 10 56 14 63 17 19
SCN4A 34365 43 1 0 5 2 3 1 4 7 3 12 2 3
SCN5A 101611 226 0 2 18 9 16 6 13 49 10 77 15 11
SERPINA1 12332 29 4 1 0 1 2 1 2 8 1 9 0 0
SERPINA7 3870 16 1 0 0 2 1 0 1 4 0 5 1 1
SLC25A20 41966 11 0 0 1 0 0 0 0 4 1 3 1 1
SLC4A1 18428 65 1 1 3 2 5 0 6 20 4 20 1 2
19
Name Length Npa NAt NAc NAg NTa NTc NTg NCa NCt NCg NGa NGt NGc
SMAD4 49535 20 0 1 1 0 0 2 1 6 3 4 1 1
SPTB 76865 18 0 0 2 2 2 2 0 6 1 0 1 2
STK11 22637 62 4 4 2 1 4 5 7 12 5 8 8 2
TAT 10242 11 0 0 0 0 1 1 0 5 1 2 1 0
TERT 41881 30 0 1 3 1 2 0 0 10 3 8 0 2
TG 267939 33 0 1 2 1 2 1 1 7 0 14 4 0
TGFBR2 87641 14 0 0 1 1 1 0 0 5 0 3 1 2
TNNI3 5966 30 0 1 5 1 1 0 0 8 2 10 0 2
TP53 20303 2003 137 113 158 121 142 109 165 284 156 252 202 164
TPI1 3287 11 0 0 1 1 1 0 0 1 0 4 1 2
TSC1 53285 44 2 0 1 1 1 2 5 19 5 5 3 0
TSC2 40724 165 7 4 6 5 13 5 22 48 18 22 10 5
TSHR 190778 45 1 0 3 1 9 2 3 8 1 12 2 3
TTR 6944 98 4 5 10 6 15 9 6 5 1 19 11 7
TYR 117888 205 10 10 22 6 16 6 16 27 13 42 26 11
UROD 3512 45 0 1 2 5 6 2 3 9 2 11 2 2
USH2A 800503 66 0 3 1 1 2 3 6 24 3 8 10 5
VHL 10444 172 5 7 12 13 22 15 7 22 21 17 18 13
WRN 140499 22 3 1 1 1 1 0 0 11 2 1 1 0
WT1 47763 56 1 2 5 1 6 3 3 13 4 11 5 2
20
